Table 1.

Patient characteristics

All patients
n (%)
Patients168 (100%)
Age at registration, year, mean ± SD(76 ± 7.7)
Tumor stage at diagnosis
 T1/245 (26.79%)
 T3/441 (24.40%)
 M145 (26.79%)
 Node positive12 (7.14%)
 Not specified25 (14.88%)
Gleason score at diagnosis
 ≤763 (37.50%)
 8–1083 (49.40%)
 Not specified22 (13.10%)
Primary treatment
 ADT (±RT)76 (45.24%)
 Radical Px (±RT)61 (36.31%)
 Radical Px + ADT5 (2.98%)
 Other15 (8.93%)
 Not specified11 (6.55%)
Previous chemotherapy
 Chemotherapy naïve100 (59.52%)
 Chemotherapy pretreated68 (40.48%)
Previous ARSi for CRPC
 No148 (88.10%)
 Yes20 (11.90%)
Initiating therapy
 Abiraterone acetate111 (66.07%)
 Enzalutamide57 (33.93%)
Metastatic burden at start therapy
 LN only20 (11.90%)
 Bone only73 (43.45%)
 Bone and LN45 (26.79%)
 Visceral and bone and/or LN26 (15.48%)
 Not specified4 (2.38%)
Baseline blood chemistryMedian (IQR)
 LDH, U/L (n = 119)335 (217–655.5)
 AP, U/L (n = 123)102 (73–160.5)
 PSA, μg/L (n = 164)36.92 (13.5–144.9)
Baseline CTCsMedian (IQR)
 CTC, #/7.5 mL (n = 164)2 (0–17.5)
  • Abbreviations: ADT, androgen deprivation therapy; AP, alkaline phosphatase; IQR, interquartile range; LDH, lactate dehydrogenase; LN, lymph node; Px, prostatectomy; RT, radiotherapy.